Download PDF
Drug Res (Stuttg) 2024; 74(06): 269-279
DOI: 10.1055/a-2331-7061
Review

Bedaquiline: An Insight Into its Clinical Use in Multidrug-Resistant Pulmonary Tuberculosis

Badruddeen,
Asad Ahmad
1   Department of Pharmacy, Integral University, Lucknow, India
,
Juber Akhtar
1   Department of Pharmacy, Integral University, Lucknow, India
,
Mohammad Ahmad
1   Department of Pharmacy, Integral University, Lucknow, India
,
Mohammad Irfan Khan
1   Department of Pharmacy, Integral University, Lucknow, India
,
Rufaida Wasim
1   Department of Pharmacy, Integral University, Lucknow, India
,
Anas Islam
1   Department of Pharmacy, Integral University, Lucknow, India
,
Aditya Singh
1   Department of Pharmacy, Integral University, Lucknow, India
› Author Affiliations Research funding This research did not receive any specific grant from any funding agencies in the public, commercial, or not-for-profit sectors.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Every year, the World Health Organization reports 500,000 new cases of drug-resistant tuberculosis (TB), which poses a serious global danger. The increased number of XDR-TB and MDR-TB cases reported worldwide necessitates the use of new therapeutic approaches. The main issues with the antitubercular medications now in use for the treatment of multidrug-resistant tuberculosis are their poor side effect profile, reduced efficacy, and antimicrobial resistance. One possible remedy for these problems is bedaquiline. The need for better treatment strategies is highlighted by the strong minimum inhibitory concentrations that bedaquiline (BDQ), a novel anti-TB medicine, exhibits against both drug-resistant and drug-susceptible TB. Bedaquiline may be able to help with these problems. Bedaquiline is a medication that is first in its class and has a distinct and particular mode of action. Bedaquiline is an ATP synthase inhibitor that is specifically directed against Mycobacterium tuberculosis and some nontuberculous mycobacteria. It is metabolized by CYP3A4. Bedaquiline preclinical investigations revealed intralesional drug biodistribution. The precise intralesional and multi-compartment pharmacokinetics of bedaquiline were obtained using PET bioimaging and high-resolution autoradiography investigations. Reduced CFU counts were observed in another investigation after a 12-week course of therapy. Meta-analyses and systematic reviews of phase II trials on bedaquilineʼs efficacy in treating drug-resistant tuberculosis in patients reported higher rates of cure, better culture conversion, and lower death rates when taken in conjunction with a background regimen. Here is a thorough medication profile for bedaquiline to aid medical professionals in treating individuals with tuberculosis.

Keywords

bedaquiline - mycobacterium tuberculosis - multidrug resistance - tuberculosis


Publication History

Received: 04 February 2024

Accepted: 06 May 2024

Article published online:
05 July 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14,70469 Stuttgart, Germany

 

  • References

  • 1 Chan B, Khadem TM, Brown J. A review of tuberculosis: Focus on bedaquiline. Am J Health Syst Pharm 2013; 70: 1984-1994
    CrossrefPubMedGoogle Scholar
  • 2 Nguyen TV, Cao TB, Akkerman OW. et al. Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis. Expert Rev. Clin. Pharmacol 2016; 9: 1025-1037
    CrossrefPubMedGoogle Scholar
  • 3 Fox GJ, Menzies D. A review of the evidence for using bedaquiline (TMC207) to treat multi-drug resistant tuberculosis. Infectious diseases and therapy 2013; 2: 123-144
    PubMedGoogle Scholar
  • 4 Van Heeswijk RP, Dannemann B, Hoetelmans RM. Bedaquiline: a review of human pharmacokinetics and drug–drug interactions. J Antimicrob Chemother 2014; 69: 2310-2318
    CrossrefPubMedGoogle Scholar
  • 5 World Health Organization. Global technical strategy for malaria 2016-2030. World Health Organization; 2015
    Google Scholar
  • 6 Harding E. WHO global progress report on tuberculosis elimination. Lancet Respir Med 2020; 1: 1-19
    PubMedGoogle Scholar
  • 7 Caminero JA. Is the DOTS strategy sufficient to achieve tuberculosis control in low-and middle-income countries? 1. Need for interventions in universities and medical schools [Unresolved Issues]. Int J Tuberc Lung Dis 2003; 7: 509-515
    PubMedGoogle Scholar
  • 8 World Health Organization. Global tuberculosis report 2013. World Health Organization; 2013
    Google Scholar
  • 9 Lohrasbi V, Talebi M, Bialvaei AZ. et al. Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance. Tuberculosis 2018; 1: 17-27
    CrossrefPubMedGoogle Scholar
  • 10 Andries K, Villellas C, Coeck N. et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLOS one 2014; 9: e102135
    PubMedGoogle Scholar
  • 11 Diacon AH, Pym A, Grobusch MP. et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732
    PubMedGoogle Scholar
  • 12 Villellas C, Coeck N, Meehan CJ. et al. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline. J Antimicrob Chemother 2017; 72: 684-690
    PubMedGoogle Scholar
  • 13 World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. World Health Organization; 2013
    Google Scholar
  • 14 Quan D, Nagalingam G, Payne R. et al. New tuberculosis drug leads from naturally occurring compounds. Int J Infect Dis 2017; 56: 212-220
    CrossrefPubMedGoogle Scholar
  • 15 Pontali E, Sotgiu G, D'Ambrosio L. et al. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J 2016; 47: 394-402
    CrossrefPubMedGoogle Scholar
  • 16 WHO. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization [cited 2024 Jan 19]. Available from: http:// www.who.int/tb/publications/pmdt_companionhandbook/en/
    PubMed
  • 17 Loddenkemper R, Sotgiu G, Mitnick CD. Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable?. Eur Res J 2012; 40: 9-11
    CrossrefPubMedGoogle Scholar
  • 18 Kakkar AK, Dahiya N. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls. Tuberculosis 2014; 94: 357-362
    CrossrefPubMedGoogle Scholar
  • 19 Esposito S, Bianchini S, Blasi F. Bedaquiline and delamanid in tuberculosis. Expert Opin Pharmacother 2015; 16: 2319-2330
    CrossrefPubMedGoogle Scholar
  • 20 Goulooze SC, Cohen AF, Rissmann R. Bedaquiline. Br J Clin Pharmacol 2015; 80: 182
    CrossrefPubMedGoogle Scholar
  • 21 Matteelli A, Carvalho AC, Dooley KE. et al. TMC207: The first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol 2010; 5: 849-858
    PubMedGoogle Scholar
  • 22 Chahine EB, Karaoui LR, Mansour H. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Ann Pharmacother 2014; 48: 107-115
    CrossrefPubMedGoogle Scholar
  • 23 Palomino JC, Martin A. TMC207 becomes bedaquiline, a new anti-TB drug. Future Microbiol 2013; 8: 1071-1080
    CrossrefPubMedGoogle Scholar
  • 24 He C, Preiss L, Wang B. et al. Structural simplification of bedaquiline: the discovery of 3-(4-(N,N-dimethylaminomethyl) phenyl) quinoline-derived antitubercular lead compounds. Chem Med Chem 2017; 12: 106-119
    CrossrefPubMedGoogle Scholar
  • 25 Savini L, Chiasserini L, Gaeta A. et al. Synthesis and anti-tubercular evaluation of 4-quinolylhydrazones. Bioorg Med Chem 2002; 10: 2193-2198
    CrossrefPubMedGoogle Scholar
  • 26 Kunin C, Ellis WY. Antimicrobial activities of mefloquine and a series of related compounds. Antimicrob Agents Chemother 2000; 44: 848-852
    CrossrefPubMedGoogle Scholar
  • 27 Kundu S, Biukovic G, Grüber G. et al. Bedaquiline targets the e subunit of mycobacterial F-ATP synthase. Antimicrob Agents Chemother 2016; 60: 6977-6979
    CrossrefPubMedGoogle Scholar
  • 28 Aguilar-Ayala DA, Cnockaert M, André E. et al. In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria. J Med Microbiol 2017; 66: 1140-1143
    CrossrefPubMedGoogle Scholar
  • 29 Hards K, Robson JR, Berney M. et al. Bactericidal mode of action of bedaquiline. J Antimicrob Chemother 2015; 70: 2028-2037
    CrossrefPubMedGoogle Scholar
  • 30 de Jonge MR, Koymans LH, Guillemont JE. et al. A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910. Proteins 2007; 67: 971-980
    CrossrefPubMedGoogle Scholar
  • 31 Lakshmanan M, Xavier AS. Bedaquiline–the first ATP synthase inhibitor against multi drug resistant tuberculosis. J Young Pharm 2013; 5: 112-115
    CrossrefPubMedGoogle Scholar
  • 32 Meier T, Polzer P, Diederichs K. et al. Structure of the rotor ring of F-type Na+ -ATPase from Ilyobacter tartaricus. Science 2005; 308: 659-662
    CrossrefPubMedGoogle Scholar
  • 33 Cholo MC, Mothiba MT, Fourie B. et al. Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline. Antimicrob Chemother 2017; 72: 338-353
    CrossrefPubMedGoogle Scholar
  • 34 Philley JV, Wallace RJ, Benwill JL. et al. Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease. Chest 2015; 148: 499-506
    CrossrefPubMedGoogle Scholar
  • 35 Gold B, Roberts J, Ling Y. et al. Rapid, semiquantitative assay to discriminate among compounds with activity against replicating or nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 2015; 59: 6521-6538
    CrossrefPubMedGoogle Scholar
  • 36 Worley MV, Estrada SJ. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis. Pharmacotherapy 2014; 34: 1187-1197
    CrossrefPubMedGoogle Scholar
  • 37 Field SK. Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?. Ther Adv Chronic Dis 2015; 6: 170-184
    CrossrefPubMedGoogle Scholar
  • 38 Matteelli A, Carvalho AC, Dooley KE. et al. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol 2010; 5: 849-858
    CrossrefPubMedGoogle Scholar
  • 39 Koul A, Vranckx L, Dendouga N. et al. Diarylquinolines are bactericidal for dormant Mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 2008; 283: 25273-25280
    CrossrefPubMedGoogle Scholar
  • 40 Huitric E, Verhasselt P, Andries K. et al. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2007; 51: 4202-4204
    CrossrefPubMedGoogle Scholar
  • 41 Rustomjee R, Diacon AH, Allen J. et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52: 2831-2835
    PubMedGoogle Scholar
  • 42 Diacon AH, Pym A, Grobusch M. et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405
    PubMedGoogle Scholar
  • 43 Rouan MC, Lounis N, Gevers T. et al. Pharmacokinetics and pharmacodynamics of TMC207 and its N-Desmethyl metabolite in a murine model of tuberculosis. Antimicrob Agents Chemother 2012; 56: 1444-1451
    CrossrefPubMedGoogle Scholar
  • 44 Diacon AH, Dawson R, Von Groote-Bidlingmaier F. et al. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother 2013; 57: 2199-2203
    CrossrefPubMedGoogle Scholar
  • 45 Koul A, Vranckx L, Dhar N. et al. Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nat Commun 2014; 5: 3369
    CrossrefPubMedGoogle Scholar
  • 46 Koul A, Vranckx L, Dhar N. et al. Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. Tuberculosis 2010; 90: 301-305
    CrossrefPubMedGoogle Scholar
  • 47 Lounis N, Veziris N, Chauffour A. et al. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother 2006; 50: 3543-3547
    CrossrefPubMedGoogle Scholar
  • 48 Ibrahim M, Andries K, Lounis N. et al. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother 2007; 51: 1011-1015
    CrossrefPubMedGoogle Scholar
  • 49 Gupta S, Tyagi S, Bishai WR. Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model. Antimicrob Agents Chemother 2014; 59: 673-676
    CrossrefPubMedGoogle Scholar
  • 50 Andries K, Villellas C, Coeck N. et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One 2014; 9: e102135
    CrossrefPubMedGoogle Scholar
  • 51 Tasneen R, Betoudji F, Tyagi S. et al. Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis. Antimicrob Agents Chemother 2015; 60: 270-277
    CrossrefPubMedGoogle Scholar
  • 52 Gupta S, Cohen KA, Winglee K. et al. Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 574-576
    CrossrefPubMedGoogle Scholar
  • 53 Mesens N, Verbeeck J, Rouan M-C. Elucidating the role of M2 in the preclinical safety profile of TMC207. Presented at: 38th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease 2007; Cape Town, South Africa.
    PubMed
  • 54 van Heeswijk RPG, Dannemann B, Hoetelmans RMW. Bedaquiline: a review of human pharmacokinetics and drug–drug interactions. J Antimicrob Chemother 2014; 69: 2310-2318
    CrossrefPubMedGoogle Scholar
  • 55 Janssen Briefing Document. TMC207 (bedaquiline): treatment of patients with MDR-TB: NDA 204-384. US Food and Drug Administration [cited 2024 Jan 19]. Available from: http://www.fda. gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM329260.pdf
    PubMed
  • 56 Fox GJ, Menzies D. A review of the evidence for using bedaquiline (TMC207) to treat multi-drug resistant tuberculosis. Infect Dis Ther 2013; 2: 123-144
    CrossrefPubMedGoogle Scholar
  • 57 Svensson EM, Dooley KE, Karlsson MO. Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. Antimicrob Agents Chemother 2014; 58: 6406-6412
    CrossrefPubMedGoogle Scholar
  • 58 Pandie M, Wiesner L, McIlleron H. et al. Drug–drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. J Antimicrob Chemother 2016; 71: 1037-1040
    CrossrefPubMedGoogle Scholar
  • 59 Dooley KE, Park JG, Swindells S. et al. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS clinical trials group study A5267. J Acquir Immune Defic Syndr 2012; 59: 455-462
    CrossrefPubMedGoogle Scholar
  • 60 Svensson EM, Aweeka F, Park JG. et al. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother 2013; 57: 2780-2787
    CrossrefPubMedGoogle Scholar
  • 61 Dooley KE, Park JG, Swindells S. et al. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new antiTB drug. J Antimicrob Chemother 2015; 70: 1106-1114
    CrossrefPubMedGoogle Scholar
  • 62 Winter H, Egizi E, Murray S. et al. Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampin and a single dose of bedaquiline in healthy adult subjects. Antimicrob Agents Chemother 2015; 59: 1219-1224
    CrossrefPubMedGoogle Scholar
  • 63 CDC. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (sirturo) for the treatment of multidrugresistant tuberculosis [cited 2024 Jan 19]. CDC. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6209a1.htm
    PubMed
  • 64 Akkerman OW, Odish OF, Bolhuis MS. et al. Pharmacokinetics of bedaquiline in cerebrospinal fluid and serum in multidrug-resistant tuberculous meningitis. Clin Infect Dis 2016; 62: 523-524
    PubMedGoogle Scholar
  • 65 Alffenaar JW, Bolhuis M, Van Hateren K. et al. Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother 2015; 59: 5675-5680
    CrossrefPubMedGoogle Scholar
  • 66 Huitric E, Verhasselt P, Koul A. et al. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2010; 54: 1022-1028
    CrossrefPubMedGoogle Scholar
  • 67 Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 2979-2981
    CrossrefPubMedGoogle Scholar
  • 68 Bloemberg GV, Keller PM, Stucki D. et al. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. N Engl J Med 2015; 373: 1986-1988
    CrossrefPubMedGoogle Scholar
  • 69 Bloemberg GV, Keller PM, Stucki D. et al. Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system. J Antimicrob Chemother 2015; 70: 2300-2305
    CrossrefPubMedGoogle Scholar
  • 70 Salfinger M, Migliori GB. Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending. Eur Respir J 2015; 45: 317-321
    CrossrefPubMedGoogle Scholar
  • 71 Rustomjee R, Diacon AH, Allen J. et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52: 2831-2835
    CrossrefPubMedGoogle Scholar
  • 72 Diacon AH, Dawson R, von Groote-Bidlingmaier F. et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med 2015; 191: 943-953
    CrossrefPubMedGoogle Scholar
  • 73 Feuerriegel S, Köser CU, Richter E. et al. Mycobacterium canettii is intrinsically resistant to both pyrazinamide and pyrazinoic acid. J Antimicrob Chemother 2013; 68: 1439-1440
    CrossrefPubMedGoogle Scholar
  • 74 Ordonez AA, Carroll LS, Abhishek S. et al. Radiosynthesis and PET Bioimaging of 76Br-Bedaquiline in a Murine Model of Tuberculosis. ACS Infect Dis 2019; 5: 1996-2002
    CrossrefPubMedGoogle Scholar
  • 75 Kaushik A, Ammerman NC, Tyagi S. et al. Activity of a Long-Acting Injectable Bedaquiline Formulation in a Paucibacillary Mouse Model of Latent Tuberculosis Infection. Antimicrob Agents Chemother 2019; 63: e00007-e00019
    CrossrefPubMedGoogle Scholar
  • 76 Rehman OU, Fatima E, Ali A. et al. Efficacy and safety of bedaquiline containing regimens in patients of drug-resistant tuberculosis: An updated systematic review and meta-analysis. J Clin Tuberc Other Mycobact Dis 2023; 1: 100405
    PubMedGoogle Scholar
  • 77 Diacon AH, Pym A, Grobusch M. et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405
    CrossrefPubMedGoogle Scholar
  • 78 Diacon AH, Donald PR, Pym A. et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56: 3271-3276
    CrossrefPubMedGoogle Scholar
  • 79 Diacon AH, Pym A, Grobusch MP. et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 37: 723-732
    CrossrefPubMedGoogle Scholar
  • 80 Janssen Briefing Document. TMC207 (bedaquiline): treatment of patients with MDR-TB: NDA 204-384. US Food and Drug Administration [cited 2024 Jan 19]. Available from: http://www.fda. gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM329260.pdf
    PubMed
  • 81 Pym AS, Diacon AH, Tang SJ. et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J 2015; 47: 564-574
    CrossrefPubMedGoogle Scholar
  • 82 Janssen Briefing Document. TMC207 (bedaquiline): treatment of patients with MDR-TB: NDA 204-384. US Food and Drug Administration [cited 2024 Jan 19]. Available from: http://www.fda. gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM329260.pdf
    PubMed
  • 83 Conradie F, Meintjes G, Hughes J. et al. Clinical Access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis. S Afr Med J 2014; 104: 164-165
    CrossrefPubMedGoogle Scholar
  • 84 CDC. Reported tuberculosis in the United States. 2016. Atlanta, GA: US Department of Health and Human Services, CDC; 2017
    Google Scholar
  • 85 Holmgaard FB, Guglielmetti L, Lillebaek T. et al. Efficacy and tolerability of concomitant use of bedaquiline and delamanid for multidrug- and extensively drug-resistant tuberculosis: a systematic review and meta-analysis. Clin Infect Dis 2023; 76: 1328-1337
    CrossrefPubMedGoogle Scholar
  • 86 Nasiri MJ, Zangiabadian M, Arabpour E. et al. Delamanid-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis. Int J Infect Dis 2023; 124: S90-S103
    CrossrefPubMedGoogle Scholar
  • 87 Franke MF, Khan P, Hewison C. et al. Culture conversion in patients treated with bedaquiline and/or delamanid. a prospective multicountry study. Am J Respir Crit Care Med 2021; 203: 111-119
    CrossrefPubMedGoogle Scholar
  • 88 Das M, Mamnoon F, Mansoor H. et al. New TB drugs for the treatment of children and adolescents with rifampicin-resistant TB in Mumbai, India. Int J tuberc Lung Dis 2020; 24: 1265-1271
    CrossrefPubMedGoogle Scholar
  • 89 Omar S, Whitfield MG, Nolan MB. et al. Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis. J Antimicrob Chemother 2024; 79: 211-40
    CrossrefPubMedGoogle Scholar
  • 90 Achar J, Hewison C, Cavalheiro AP. et al. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis. Emerg Infect Dis 2017; 23: 1711-1713
    CrossrefPubMedGoogle Scholar
  • 91 Esposito S, Bianchini S, Argentiero A. et al. How does one choose the appropriate pharmacotherapy for children with lower respiratory tract infections?. Expert Opin Pharmacother 2020; 21: 1739-1747
    CrossrefPubMedGoogle Scholar
  • 92 Mbuagbaw L, Guglielmetti L, Hewison C. et al. Outcomes of bedaquiline treatment in patients with multidrug-resistant tuberculosis. Emerg Infect Dis 2019; 25: 936
    CrossrefPubMedGoogle Scholar
  • 93 Salhotra VS, Sachdeva KS, Kshirsagar N. et al. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: an interim analysis. Indian J Tuberc 2020; 67: 29-37
    CrossrefPubMedGoogle Scholar
  • 94 Mbuagbaw L. Review of available evidence on the use of bedaquiline for the treatment of multidrug-resistant tuberculosis: data analysis report March 8, Version 2017, version 6. WHO; 2017
    Google Scholar
  • 95 World Health Organization (WHO). Budgeting for TB control activities. Geneva, Switzerland: WHO; http://www.who.int/tb/dots/planning_budgeting_tool/en/index.html
    Google Scholar
  • 96 Ionescu A-M, Mpobela Agnarson A, Kambili C. et al. Bedaquiline-versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res 2018; 18: 677-689
    CrossrefPubMedGoogle Scholar